{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6s38sJDA","lastupdate":"2023-09-20T00:00:00.000Z","update_date":"2023-09-20T00:00:00.000Z","lastModified":"Oct 28, 2025","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"regentis-biomaterials","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Sep, 2025;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$l0tCy2zjZMr2UFYBYBkNNllBGttEUbDfajNlYcjnStJ50gW6vAyoou.jpeg","name":"Regentis Biomaterials","oneliner":"Implantable Hydrogel Platform for Tissue Regeneration","registrar":"513585240","website":"https://www.regentis.co.il","careerspage":"","founded_month":9,"founded_year":2004,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UCY231jR34KUS6RMeh6GbA0g","facebook":"","linkedin":"https://www.linkedin.com/company/6144951","instagram":""},"social":["https://www.linkedin.com/company/6144951","https://www.youtube.com/channel/UCY231jR34KUS6RMeh6GbA0g"],"flattenedsociallinks":"https://www.linkedin.com/company/6144951|https://www.youtube.com/channel/UCY231jR34KUS6RMeh6GbA0g","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":3,"patent":0,"raised":43500000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"Regentis Biomaterials is a tissue-repair company developing and commercializing a hydrogel platform for the repair of damaged tissue. Its current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue.\r\n\r\nThe company's first commercial product is GelrinC, a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage. After standard microfracture, the hydrogel is injected as a liquid and conforms to the lesion's size, shape, and depth, with no cutting or press fitting required to fill the lesion.\r\n\r\nAfter brief exposure to UV light, the hydrogel becomes a semisolid implant tightly integrated with the surrounding tissue and bone with no fibrin glue necessary to secure it in place. The implant acts as a scaffold, gradually eroding over time as new cartilage takes its place. GelrinC is completely resorbed in vivo within 6 to 12 months.\r\n\r\nThe manufacturing process of GelrinC meets strict international safety, quality, and biocompatibility standards, including GMP and ISO 13485.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97246265502","country":null,"address":{"israeli":[{"id":"cbbdd1b3-9746-4743-9206-64a7e376d2a7","city":"Or Akiva","type":null,"address":"Hailan Street 12, Or Akiva, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"1fc6afd1-e87f-47a9-baf6-e6cb83274944","city":"Princeton","address":"Princeton, NJ, USA","country":"United States","placeid":null},{"id":"f35b1d44-d542-4e68-98b1-9bf05cc152df","city":"Mnster","address":"Borkstrae 10, 48163, Mnster, Germany","country":"Germany","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"6FTGS7nK31KDj5Lr0OA65uG4dCm3MJ7TLUj9GtNJ3B8iRXX2dfSdxQ","date":"May 3, 2023","link":"https://news.spacconference.com/2023/05/03/regentis-biomaterials-combining-with-oceantech-acquisitions-i-in-95m-deal/","source":"news.spacconference.com","visible":1,"analysis":{"tags":"Merger, Management Changes","company":"OceanTech Acquisitions I, Regentis Biomaterials","layoffs":"Not mentioned","summary":"OceanTech Acquisitions I has announced a definitive merger agreement with Israel-based Regentis Biomaterials at a $95 million valuation. The all-stock deal will see Regentis shareholders receive $95 million of OceanTech shares. Regentis is a regenerative medicine company developing tissue repair solutions, currently focusing on orthopedic treatments using its Gelrin platform. OceanTech has previously made two unsuccessful merger attempts and underwent a complete change in management in March. The SPAC raised $100 million in a May 2021 IPO with initial plans to target marine and IT industries.","partners":"Maxim Group, Cohen & Company Capital Markets, Greenberg Traurig, Doron Tikotzky Kantor Gutman Nass & Amit Gross & Co., Nelson Mullins Riley & Scarborough, Goldfarb Gross Seligman & Co., Pryor Cashman","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Merger Agreement","Regenerative Medicine","Orthopedic Treatments","Management Change","Financial Advisors"],"date_of_event":"Not mentioned","valuation_amount":"$95 million","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Acquisition","Management Changes"],"acquisition_amount":"$95 million","structuredIssuesShow":"#Acquisition  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"hWvikhptAVVWbQvSFhjUal5A4IadSkCNVW2CMHVhS6n59Be8RSgT2W","news_summary":"Regentis Biomaterials Combining with OceanTech Acquisitions I in $95M Deal | DealFlow's SPAC News","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tpeYIolQ7SLSMj1EuHyALjYgBSBCSblntPFmVjoS6ZFGLxdmSlmUCZ","date":"May 3, 2023","link":"https://www.businesswire.com/news/home/20230503005563/en/Regentis-Biomaterials-Ltd-to-Become-Publicly-Listed-on-Nasdaq-via-Business-Combination-with-OceanTech-Acquisitions-I-Corp.","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"XNy6gMYBt4TFGZKHRsglRdDt4wlW0r2hX1vkoBb5A7Jkb78SPZ393y","news_summary":"Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c95ad8f9-88d6-4e3c-aa1f-10a934a47f5e","date":"Nov 27, 2018","link":"https://www.apnews.com/7968f41299e34365b1d8472069bf9fa9","source":"www.apnews.com","visible":1,"analysis":{"tags":"medical technology","company":"Regentis Biomaterials","layoffs":null,"summary":"Regentis Biomaterials announced that TRIA Orthopedics is the first in Minnesota to use the GelrinC implant to treat damaged articular cartilage causing knee pain. GelrinC is being evaluated as a treatment to help the body regrow cartilage in the knee. The current standard of care is microfracture, which provides only short-term relief. GelrinC, on the other hand, requires only a single minimally invasive procedure and may promote long-term repair of the cartilage. The GelrinC implant is part of the SAGE clinical trial, which is comparing GelrinC to microfracture. Regentis Biomaterials is a privately held company focused on developing hydrogels for tissue regeneration.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["GelrinC implant","articular cartilage","knee pain","clinical trial","tissue regeneration"],"date_of_event":"November 27, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ILBwusFkrsy2it32YaZtrS7lzKf7yXe3Ta3MZlZnyElnm64SND5qCE","news_summary":"TRIA Orthopedics First in Minnesota to Test Breakthrough GelrinC™ Implant to Regenerate Knee Cartilage","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"963729b0-c229-4bf9-9b3c-319e5af2a413","date":"Oct 23, 2018","link":"https://www.businesswire.com/news/home/20181023005469/en/Regentis-Biomaterials-Expands-SAGE-Clinical-Trial-GelrinC%E2%84%A2","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"FexReMcjjxEm1kyJGeElOUS2vaw5wuOvEZPlcFHwSRnqhR3mYswL7g","news_summary":"Regentis Biomaterials Expands SAGE Clinical Trial of GelrinC™ for Knee Pain","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bd5e5a94-b227-42e1-9032-c4130f337e9a","date":"Nov 28, 2017","link":"https://www.prnewswire.com/news-releases/regentis-biomaterials-performs-the-first-cases-in-gelrinc-pivotal-study-660509563.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Regentis Biomaterials","layoffs":null,"summary":"Regentis Biomaterials has started its Phase III pivotal clinical trial of GelrinC for the treatment of focal knee cartilage defects. The trial involves successful surgeries on three patients in the US and Denmark and aims to compare GelrinC to the current standard of care treatment. The trial will support a Pre-market Approval Application (PMA) to market GelrinC in the US. The procedures were performed by Dr. Jason Scopp and Dr. Bryan Huber in the US, and Dr. Martin Lind in Denmark. Regentis President and CEO Alastair Clemow stated that the success of the procedures is a significant milestone for the company and will help patients recover from damaged knee cartilage.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Phase III","GelrinC","clinical trial","cartilage defects","FDA"],"date_of_event":"November 28, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OMyzt7vZkxXd0zgwpz0OtjlzU6DhjmxoaVzmteYEJYGHptvGAXAg3L","news_summary":"Regentis Biomaterials Performs the First Cases in Gelrinc Pivotal Study","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ab7c3656-638e-4932-a733-7f542a75e91a","date":"Aug 28, 2017","link":"https://www.prnewswire.com/news-releases/regentis-biomaterials-receives-european-ce-mark-approval-for-gelrinc-641994703.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"CE mark approval","company":"Regentis Biomaterials Ltd.","layoffs":null,"summary":"Regentis Biomaterials has received European CE mark approval for its GelrinC biodegradable implant, allowing the company to access new global markets and help more patients with damaged articular knee cartilage. The approval expands upon the existing CE mark for a version containing denatured bovine-sourced fibrinogen. GelrinC is designed to treat articular knee cartilage defects and has shown positive results in clinical studies. Regentis is currently conducting a Phase III clinical trial in the US and Europe to support FDA approval. The company sees a potential market of over 150,000 procedures in the US alone.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["CE mark approval","GelrinC biodegradable implant","articular knee cartilage","clinical study","tissue regeneration"],"date_of_event":"August 28, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"c3NL8kXVNgjuctYCInDVuXxl2BhwNLLjJdiVXkwUbCARM8coLbqzDq","news_summary":"Regentis Biomaterials Receives European CE Mark Approval for GelrinC","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8074c9ca-2ef0-4543-b353-c6ea0cdacee3","date":"Sep 26, 2016","link":"http://www.prnewswire.com/news-releases/regentis-receives-ide-approval-for-pivotal-gelrinc-clinical-trial-594800251.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"medical, FDA approval","company":"Regentis Biomaterials","layoffs":null,"summary":"Regentis Biomaterials has received FDA approval to initiate a Phase III clinical study of GelrinC, a treatment for focal cartilage defects in the knee. The cartilage repair market is estimated to be worth over $1 billion. The GelrinC procedure is easy and quick for surgeons to perform and can be carried out using a minimally invasive approach. The FDA trial will evaluate the safety and efficacy of GelrinC compared to a historical microfracture control arm. Regentis Biomaterials is a privately held company focused on developing and commercializing hydrogels for tissue regeneration.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["FDA approval","clinical study","cartilage repair","GelrinC","Regentis Biomaterials"],"date_of_event":"September 26, 2016","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cxfXbtMirioc7aa677HOCOLy4Tj8qdSSRRFZpg3CRtVwszUJt0aQqJ","news_summary":"Regentis Receives IDE Approval for Pivotal GelrinC Clinical Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"078d1c8d-b587-4706-b4f5-ebb53a07a565","date":"Feb 7, 2016","link":"http://www.globes.co.il/en/article-cartilage-treatment-co-regentis-biomaterials-raises-15m-1001101278","source":"www.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"Regentis Biomaterials","layoffs":null,"summary":"Chinese pharmaceutical group Haisco led a $15 million Series D financing round in Israeli startup Regentis Biomaterials, bringing the total raised by the company to $35 million. Regentis Biomaterials develops products to treat damaged cartilage and is currently conducting clinical trials for its flagship product, GelrinC. The company already has approval for sale in Europe and plans to begin clinical trials for FDA approval in the US. The investment from Haisco and other existing investors will help Regentis Biomaterials expand its technological potential for the Chinese market.","partners":null,"customers":null,"investors":"Haisco, Medica Venture Partners, SCP Vitalife Partners, Generali Investment, T3","confidence":9,"key_topics":["Regentis Biomaterials","Haisco","investment","cartilage treatment","clinical trials"],"date_of_event":"February 7, 2016","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$15 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AE8Xn0bMA3jLfWQpwBP2z4RlBUhSsUo5sTeNhN7CUToMTJtUOZJ8I9","news_summary":"Regentis Biomaterials raises $15m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"249773b5-5293-42b6-a198-0778f6bd3db0","date":"Oct 4, 2013","link":"https://ryortho.com/breaking/regentis-reports-articular-cartilage-repair/","source":"ryortho.com","visible":1,"analysis":{"tags":"medical technology","company":"Regentis Biomaterials, Ltd","layoffs":null,"summary":"Regentis Biomaterials announces favorable clinical data for its GelrinC implant for treating articular cartilage in injured knees. The implant is a biodegradable hydrogel that degrades within 6-12 months and is replaced with functional and durable cartilage created by stem cells. A recent study showed substantial improvement in patient outcomes, with a 43% improvement in the Knee injury and Osteoarthritis Outcome Score (KOOS) and an 86% improvement in the subjective questionnaire. The GelrinC implant works in combination with the microfracture procedure to enhance the bodys ability to regenerate new cartilage. The company is focused on developing and commercializing proprietary hydrogels for tissue regeneration.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["GelrinC implant","articular cartilage","clinical data","knee injuries","tissue regeneration"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KelNp3dMGnGGEYY5zooRWqnETqsbCzs0KIhhGSon2E1hltJL6TpDmY","news_summary":"Regentis Reports Articular Cartilage Repair","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1adea449-755c-4555-add3-a8c52c35b2db","date":"May 15, 2012","link":"http://www.healio.com/orthopedics/biologics/news/online/%7B9b811f9d-b685-445a-a766-4848e702e4a2%7D/investments-allow-further-research-expansion-for-regentis-biomaterials","source":"www.healio.com","visible":1,"analysis":{"tags":"investment","company":"Regentis Biomaterials Ltd.","layoffs":null,"summary":"Regentis Biomaterials Ltd. has received a $10 million investment to continue promoting GelrinC, a biodegradable implant that increases the growth of articular cartilage in damaged knee joints. The investment will also allow the company to expand its clinical efforts and demonstrate the effectiveness of GelrinC in regenerating cartilage. GelrinC is currently undergoing clinical trials and is not yet available in the United States, Europe, and Israel. The investment is expected to support the companys growth and help patients return to an active lifestyle.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Regentis Biomaterials","GelrinC","hydrogels","tissue regeneration","clinical trials"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"o00gZEZq4uEF0qh1dbnUFE7qPejK38S1MIxImXDW0o2BQ7YAIcnKI5","news_summary":"Investments allow further research, expansion for Regentis Biomaterials","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":10,"techcommunityinvolvement":null,"mediagallery":[{"id":"bfcb71f4-50f7-4b66-b97c-47695d3224fa","timestamp":"2020-08-02 07:42:47.000000","resources_type":2,"resources_title":"","resources_file_name":"uoWr6D-P7Hk","alt":"","imageurl":"https://img.youtube.com/vi/uoWr6D-P7Hk/0.jpg","url":"http://youtu.be/uoWr6D-P7Hk"},{"id":"3d758549-ebe7-4a23-9c65-b7ec80a4d30d","timestamp":"2019-11-11 11:40:35.000000","resources_type":2,"resources_title":"What is GelrinC? | GelrinC Implant | SAGE Study","resources_file_name":"xyUTeVS1N_g","alt":"What is GelrinC? | GelrinC Implant | SAGE Study logo","imageurl":"https://img.youtube.com/vi/xyUTeVS1N_g/0.jpg","url":"http://youtu.be/xyUTeVS1N_g"},{"id":"520a7334-75cc-4945-be4e-b116bc63947b","timestamp":"2019-03-18 09:40:12.000000","resources_type":2,"resources_title":"GelrinC Implant | Procedure Animation | Articular Cartilage Repair | Regentis Biomaterials","resources_file_name":"S73oKsbq8hc","alt":"GelrinC Implant | Procedure Animation | Articular Cartilage Repair | Regentis Biomaterials logo","imageurl":"https://img.youtube.com/vi/S73oKsbq8hc/0.jpg","url":"http://youtu.be/S73oKsbq8hc"},{"id":"90df7777-5c6c-4f4c-8157-220844d33fef","timestamp":"2019-03-18 09:39:57.000000","resources_type":2,"resources_title":"GelrinC Implant | Narrated Procedure Animation | Articular Cartilage Repair | Regentis Biomaterials","resources_file_name":"waX2dpbXztA","alt":"GelrinC Implant | Narrated Procedure Animation | Articular Cartilage Repair | Regentis Biomaterials logo","imageurl":"https://img.youtube.com/vi/waX2dpbXztA/0.jpg","url":"http://youtu.be/waX2dpbXztA"}],"tags":["biomaterials","medical-devices","orthopedics","medical-technologies","tissue-regeneration","regenerative-medicine","surgery","biodegradable","pain-relief","drug-delivery","nanotechnology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":[{"date":"2004-09-01","name":"Implantable Hydrogel Platform for Tissue Regeneration","tags":["biomaterials","regenerative-medicine"],"category":"Medical Devices","tto_logo":"/image_cloud/t3_tto_logo_f5fde2b3-6016-11e8-abf1-41fdcbb0dda6","university_logo":"/image_cloud/t3_institution_logo_f5fde2b3-6016-11e8-abf1-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["GelrinC"],"geomarkets":["Germany","Netherlands","Belgium","Poland","Denmark","United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":8,"lastfunding":"$11M","totalrounds":4,"fundingstage":"Public","totalfunding":"$43.5M","publicinvestors":8,"lastpublicfunding":11000000,"totalpublicrounds":4,"totalpublicfunding":43500000},"team":[{"name":"Prof. Dror  Seliktar","email":"dror@regentis.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LCfhM4IDA","bounced":true,"claimed":0,"founder":1,"urlname":"prof-dror-seliktar","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgqK_IxwoM","position":"Co-Founder & CSO","last_name":"Seliktar","claimtoken":"3mNTpwgKAyhjezUKSOkQMQQM63ygU46WHGqB6kfPE5Z6UMDYmVcta1","first_name":"Prof. Dror ","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"dseliktar@regentis.co.il","claimedemaildate":"2023-09-20 10:00:38.000000","initials":"PS","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Arie Gordashnikov","email":"arie@regentis.co.il","phone":"","gender":"Male","userid":"IqtppapIqGpBCWLPr1ssf2xvCc2pt469sjMkQHUasHiAGsTMfdtMHA","bounced":true,"claimed":null,"founder":0,"urlname":"arie-gordashnikov","visible":1,"memberid":"sK3EdDl3lX61iDtzQvB0xgWR299AQnsnU5J2Hc0fSBpOPcEcjKtREG","position":"CFO","last_name":"Gordashnikov","claimtoken":"sF47jTSiSJXMe1MjzES8txnKXsm8T3cblNVYKvP1WLvhRoxjBX6uVe","first_name":"Arie","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/arie-gordashnikov-cpa-mba-36278564/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-09-20 11:07:02.000000","initials":"AG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2019-11-11T00:00:00.000Z","crunchbaseid":"regentis-biomaterials","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":"Rebecca Mack","creator_email":"rebeccamack26@gmail.com","createdate":"2014-07-30T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Sharon Shapira","affiliatedOrganizations":null,"timeline":[{"id":"vMVh7pDwJxEdmV60XPep62SXYunbak2aAV9FB3384ARVoR0jUOABPc","date":"Sep 2025","amount":"Undisclosed","source":"https://thefly.com/landingPageNews.php?id=4194608&headline=RGNT-Regentis-Biomaterials-M-share-IPO-price-range-1757347105C99&test2","ticker":"RGNT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$11M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":11000000,"valuationnumber":null},{"id":"5f2hmP4CnJgMIpfD6bO0QwJnzUCcqrhxwaFbbiaQ5Af2jfE8saapHP","date":"May 2023","amount":"$95M","source":"https://www.businesswire.com/news/home/20230503005563/en/Regentis-Biomaterials-Ltd-to-Become-Publicly-Listed-on-Nasdaq-via-Business-Combination-with-OceanTech-Acquisitions-I-Corp.  , https://news.spacconference.com/2023/05/03/regentis-biomaterials-combining-with-oceantech-acquisitions-i-in-95m-deal/","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"OceanTech Acquisitions ","acquiredcompany_mna_id":"1VPhA6RxdjhfIt87yoNJIdxeaKukKr4MdocE1FYK0E8Ok0A8oQO2ff","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/oceantech-acquisitions","acquiredcompany_mna_logokey":"$y1vSHjSTEHiRhuh7a4GE7075lRzcxvQ39OfjkF9DBkZDFGhAogyWud.jpeg","acquiredcompany_mna_urlname":"/company_page/oceantech-acquisitions","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$y1vSHjSTEHiRhuh7a4GE7075lRzcxvQ39OfjkF9DBkZDFGhAogyWud.jpeg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":95000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmseJCQw","date":"Feb 2016","amount":"$15M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"General Oriental Investments","type":"Holding Company","amount":0,"hidden":false,"country":"Switzerland","fullurl":"/company_page/general-oriental-investments","logokey":"$H6yxDv3Hl4HGlZJnFyc0hiXn7spD8MDmtt65mtaxZWx6Z1L0X4lxsW","tagline":"","urlname":"/company_page/general-oriental-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJC8t_PvCQw","fundingtype":"Holding Company","leadpartner":null,"investmentid":"340ad94c-1d75-45d4-9ad6-d3f9289931d7","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$H6yxDv3Hl4HGlZJnFyc0hiXn7spD8MDmtt65mtaxZWx6Z1L0X4lxsW","leadcaption":"","followupcaption":""},{"name":"Haisco","type":"Company","amount":0,"hidden":true,"country":"China","fullurl":"/company_page/haisco","logokey":"$zPWUfpp2cqf5llqUwrtv6N1NCcSDY93LkhjxycAU4unnPDpdLJHxfT","tagline":"Research and Development of Therapeutic Drugs","urlname":"/company_page/haisco","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk7ruICQw","fundingtype":"Company","leadpartner":null,"investmentid":"65249d34-8b17-42b9-9334-12fd10a30484","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zPWUfpp2cqf5llqUwrtv6N1NCcSDY93LkhjxycAU4unnPDpdLJHxfT","leadcaption":"","followupcaption":""},{"name":"Medica Venture Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medica-venture-partners","logokey":"$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","tagline":null,"urlname":"/investor_page/medica-venture-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNGd6ZUJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9475fd61-eebf-4fe0-871a-4175bc1fda41","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","leadcaption":"","followupcaption":"Follow on "},{"name":"SCP Vitalife","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/scp-vitalife","logokey":"$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","tagline":null,"urlname":"/investor_page/scp-vitalife","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnPn5EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ab866d34-5542-45be-9c28-1913c4baa4de","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","leadcaption":"","followupcaption":"Follow on "},{"name":"T3","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/t3-1","logokey":"$wccFrrTTE4Kxc7nne4oY5hBzBCka3gPsQwNqVQUAVDlQJUn8hzGGOc","tagline":"Technology Transfer Office of Technion","urlname":"/company_page/t3-1","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzebACgw","fundingtype":"Other","leadpartner":null,"investmentid":"dc1ea09f-ab27-4e86-84c4-2e7ef83dd462","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wccFrrTTE4Kxc7nne4oY5hBzBCka3gPsQwNqVQUAVDlQJUn8hzGGOc","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"D Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":15000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEqNqHCgw","date":"May 2012","amount":"$10M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"SCP Vitalife","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/scp-vitalife","logokey":"$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","tagline":null,"urlname":"/investor_page/scp-vitalife","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnPn5EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7c865490-f14d-463f-b567-bb159ce57dab","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","leadcaption":"","followupcaption":"Follow on "},{"name":"Medica Venture Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medica-venture-partners","logokey":"$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","tagline":null,"urlname":"/investor_page/medica-venture-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNGd6ZUJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"81a8a7f1-ced6-4b04-bab3-cec909511e38","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","leadcaption":"","followupcaption":""},{"name":"Crossroad Venture Capital Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/crossroad-venture-capital-fund","logokey":"$Frw2Ft37l1uIGXC7Xuc4ZfcOfmzp7ufgb0Kfy3qKnNxXN1IFBMKJsN","tagline":null,"urlname":"/investor_page/crossroad-venture-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJGls48JDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"DkaZHgRCMOHy9mpxqCiZG6I5Mq7RTVvr9NdmJswyMgF8Qe1buFfE9Y","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Frw2Ft37l1uIGXC7Xuc4ZfcOfmzp7ufgb0Kfy3qKnNxXN1IFBMKJsN","leadcaption":"","followupcaption":""},{"name":"DSM Venturing","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/dsm-venturing","logokey":"$b9lB6ooT9q7LnSEHFMHYaHJJQjfV9gCLGU5ttZsNTdPX8C2rbpUaGu","tagline":"","urlname":"/investor_page/dsm-venturing","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5Y20CAw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"f5f48cf3-998f-467a-bc3c-02f86e870332","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$b9lB6ooT9q7LnSEHFMHYaHJJQjfV9gCLGU5ttZsNTdPX8C2rbpUaGu","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODE27vvCAw","date":"Apr 2008","amount":"$7.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"SCP Vitalife","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/scp-vitalife","logokey":"$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","tagline":null,"urlname":"/investor_page/scp-vitalife","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnPn5EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4dfb652d-89ef-429b-b771-08ae692b2904","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","leadcaption":"","followupcaption":""},{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"90367ae3-6878-401d-b0bf-401720ea1ef0","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"9/2004","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Regentis Biomaterials","logourl":"https://storage.googleapis.com/clean-finder-353810/$l0tCy2zjZMr2UFYBYBkNNllBGttEUbDfajNlYcjnStJ50gW6vAyoou.jpeg","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$l0tCy2zjZMr2UFYBYBkNNllBGttEUbDfajNlYcjnStJ50gW6vAyoou.jpeg","seoabout":"Regentis Biomaterials is a tissue-repair company developing and commercializing a hydrogel platform for the repair of damaged tissue. Its current efforts a...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":2,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]},{"title":"Pharma & Medical Biotechnology","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Biomaterials & Tissue Engineering","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Biomaterials & Tissue Engineering"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics","Pharma & Medical Biotechnology","Biomaterials & Tissue Engineering"],"coreTechnology":["Materials & Substances"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"vMVh7pDwJxEdmV60XPep62SXYunbak2aAV9FB3384ARVoR0jUOABPc","date":"Sep 2025","amount":"Undisclosed","source":"https://thefly.com/landingPageNews.php?id=4194608&headline=RGNT-Regentis-Biomaterials-M-share-IPO-price-range-1757347105C99&test2","ticker":"RGNT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$11M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":11000000,"valuationnumber":null}],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmseJCQw","date":"Feb 2016","amount":"$15M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"General Oriental Investments","type":"Holding Company","amount":0,"hidden":false,"country":"Switzerland","fullurl":"/company_page/general-oriental-investments","logokey":"$H6yxDv3Hl4HGlZJnFyc0hiXn7spD8MDmtt65mtaxZWx6Z1L0X4lxsW","tagline":"","urlname":"/company_page/general-oriental-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJC8t_PvCQw","fundingtype":"Holding Company","leadpartner":null,"investmentid":"340ad94c-1d75-45d4-9ad6-d3f9289931d7","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$H6yxDv3Hl4HGlZJnFyc0hiXn7spD8MDmtt65mtaxZWx6Z1L0X4lxsW","leadcaption":"","followupcaption":""},{"name":"Haisco","type":"Company","amount":0,"hidden":true,"country":"China","fullurl":"/company_page/haisco","logokey":"$zPWUfpp2cqf5llqUwrtv6N1NCcSDY93LkhjxycAU4unnPDpdLJHxfT","tagline":"Research and Development of Therapeutic Drugs","urlname":"/company_page/haisco","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk7ruICQw","fundingtype":"Company","leadpartner":null,"investmentid":"65249d34-8b17-42b9-9334-12fd10a30484","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zPWUfpp2cqf5llqUwrtv6N1NCcSDY93LkhjxycAU4unnPDpdLJHxfT","leadcaption":"","followupcaption":""},{"name":"Medica Venture Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medica-venture-partners","logokey":"$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","tagline":null,"urlname":"/investor_page/medica-venture-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNGd6ZUJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9475fd61-eebf-4fe0-871a-4175bc1fda41","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","leadcaption":"","followupcaption":"Follow on "},{"name":"SCP Vitalife","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/scp-vitalife","logokey":"$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","tagline":null,"urlname":"/investor_page/scp-vitalife","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnPn5EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ab866d34-5542-45be-9c28-1913c4baa4de","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","leadcaption":"","followupcaption":"Follow on "},{"name":"T3","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/t3-1","logokey":"$wccFrrTTE4Kxc7nne4oY5hBzBCka3gPsQwNqVQUAVDlQJUn8hzGGOc","tagline":"Technology Transfer Office of Technion","urlname":"/company_page/t3-1","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzebACgw","fundingtype":"Other","leadpartner":null,"investmentid":"dc1ea09f-ab27-4e86-84c4-2e7ef83dd462","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wccFrrTTE4Kxc7nne4oY5hBzBCka3gPsQwNqVQUAVDlQJUn8hzGGOc","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"D Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":15000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEqNqHCgw","date":"May 2012","amount":"$10M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"SCP Vitalife","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/scp-vitalife","logokey":"$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","tagline":null,"urlname":"/investor_page/scp-vitalife","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnPn5EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7c865490-f14d-463f-b567-bb159ce57dab","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","leadcaption":"","followupcaption":"Follow on "},{"name":"Medica Venture Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medica-venture-partners","logokey":"$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","tagline":null,"urlname":"/investor_page/medica-venture-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNGd6ZUJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"81a8a7f1-ced6-4b04-bab3-cec909511e38","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BRsqGN8c4r4WUbbP83yyreqYlaBTeFcQrT7KgVUBuYwsEJz0JQNEhO","leadcaption":"","followupcaption":""},{"name":"Crossroad Venture Capital Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/crossroad-venture-capital-fund","logokey":"$Frw2Ft37l1uIGXC7Xuc4ZfcOfmzp7ufgb0Kfy3qKnNxXN1IFBMKJsN","tagline":null,"urlname":"/investor_page/crossroad-venture-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJGls48JDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"DkaZHgRCMOHy9mpxqCiZG6I5Mq7RTVvr9NdmJswyMgF8Qe1buFfE9Y","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Frw2Ft37l1uIGXC7Xuc4ZfcOfmzp7ufgb0Kfy3qKnNxXN1IFBMKJsN","leadcaption":"","followupcaption":""},{"name":"DSM Venturing","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/dsm-venturing","logokey":"$b9lB6ooT9q7LnSEHFMHYaHJJQjfV9gCLGU5ttZsNTdPX8C2rbpUaGu","tagline":"","urlname":"/investor_page/dsm-venturing","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5Y20CAw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"f5f48cf3-998f-467a-bc3c-02f86e870332","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$b9lB6ooT9q7LnSEHFMHYaHJJQjfV9gCLGU5ttZsNTdPX8C2rbpUaGu","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODE27vvCAw","date":"Apr 2008","amount":"$7.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"SCP Vitalife","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/scp-vitalife","logokey":"$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","tagline":null,"urlname":"/investor_page/scp-vitalife","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnPn5EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4dfb652d-89ef-429b-b771-08ae692b2904","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$TyfWACBDu3BOb9eodv9xAcJ9GEsrfMgp8CYZOMixTusvVV9wc20mqD","leadcaption":"","followupcaption":""},{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"90367ae3-6878-401d-b0bf-401720ea1ef0","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[{"id":"5f2hmP4CnJgMIpfD6bO0QwJnzUCcqrhxwaFbbiaQ5Af2jfE8saapHP","date":"May 2023","amount":"$95M","source":"https://www.businesswire.com/news/home/20230503005563/en/Regentis-Biomaterials-Ltd-to-Become-Publicly-Listed-on-Nasdaq-via-Business-Combination-with-OceanTech-Acquisitions-I-Corp.  , https://news.spacconference.com/2023/05/03/regentis-biomaterials-combining-with-oceantech-acquisitions-i-in-95m-deal/","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"OceanTech Acquisitions ","acquiredcompany_mna_id":"1VPhA6RxdjhfIt87yoNJIdxeaKukKr4MdocE1FYK0E8Ok0A8oQO2ff","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/oceantech-acquisitions","acquiredcompany_mna_logokey":"$y1vSHjSTEHiRhuh7a4GE7075lRzcxvQ39OfjkF9DBkZDFGhAogyWud.jpeg","acquiredcompany_mna_urlname":"/company_page/oceantech-acquisitions","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$y1vSHjSTEHiRhuh7a4GE7075lRzcxvQ39OfjkF9DBkZDFGhAogyWud.jpeg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":95000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}